Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet

Bone disease is a common clinical problem following renal transplantation. In renal transplant recipients, multiple underlying factors determine the extent of bone loss and the subsequent risk of fractures. In addition to the well-recognized risk to bone disease posed by steroids, calcineurin inhibitors and pre-existing bone disease, persistent hyperparathyroidism (HPT) contributes to post-transplant bone loss. HPT is usually treated with vitamin D supplements combined with calcium. Patients whose HPT is associated with hypercalcemia pose a difficult therapeutic dilemma which often requires parathyroidectomy. Cinacalcet, a calcium mimetic agent, offers a unique pharmacologic approach to the treatment of patients with post-transplant hypercalcemia and HPT. In this paper, we describe the clinical course and biochemical changes in 10 renal transplant recipients with hypercalcemia and severe HPT early after renal transplantation treated with cinacalcet. Cinacalcet therapy corrected hypercalcemia and decreased parathyroid hormone (PTH) levels in all cases. A transient rise in the level of alkaline phosphatase was noted following initiation of cinacalcet therapy. In this patient population, correction of HPT was not permanent as discontinuing cinacalcet therapy led to a rapid rise in PTH level.

Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome

Rituximab is a chimaeric monoclonal antibody directed against the CD20 antigen. It has been successfully used in B-cell malignancy and its efficacy in the treatment of in autoimmune hemolytic anemia and other autoimmune diseases is being investigated. There are also few case reports of its success in thrombotic thrombocytopenic purpura, but no reports of its use in hemolytic-uremic syndrome (HUS). We report a 36-year-old patient who had lost the function of her native kidneys secondary to HUS. After more than 1 year in clinical remission, she received a living unrelated kidney transplant. This immediately precipitated a severe relapse of HUS. The process was abrogated but not completely inactivated, despite over 40 plasma exchange treatments. Consequently, she was given Rituximab in courses of two to three doses, each dose 375 mg/m(2), at weekly intervals with remarkable stabilization of her disease for approximately 6 months.

Perioperative evaluation of a new mixed venous oxygen saturation catheter in cardiac surgical patients

Fiberoptic pulmonary artery flotation catheters have gained clinical acceptance for continuous monitoring of mixed venous oxygen saturation (SvO2), especially in the management of hemodynamically unstable patients. Therefore, the performance of the oximetry system used is extremely important. The accuracy and stability of a new two-wavelength oximetry pulmonary artery catheter and SAT-2 oximeter were assessed in adult patients during and following cardiac surgery. After in vitro calibration of the system, the catheter was inserted through the right internal jugular vein and positioned in the pulmonary artery prior to induction of anesthesia. During the study period, the system was updated for hemoglobin changes of 1.8 g/dL or more. In vivo SvO2 values obtained by the oximetry catheter were compared with those determined with a reference oximeter from simultaneously drawn mixed venous blood specimens at different intervals. A total of 604 paired data points from 52 patients were analyzed, 572 (94.7%) of which were within the 95% confidence interval. Overall bias was -1.7% +/- 3.5% (SD). The results suggest that over the time course of the study, in vivo SvO2 values obtained with the two-wavelength catheter and the SAT-2 oximeter closely approximated SvO2 measured with a reference oximeter from mixed venous blood samples (r = 0.917; SEE 3.5%) in cardiac surgical patients in whom marked physiological changes occur.